CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model
Open Access
- 9 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (69) , 114095-114108
Abstract
CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft modelKeywords
This publication has 45 references indexed in Scilit:
- EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistanceJournal of Experimental & Clinical Cancer Research, 2015
- CD44-mediated activation of α5β1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and Fibronectin-enriched matricesOncotarget, 2015
- CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaScientific Reports, 2015
- Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axisOncotarget, 2013
- New molecular insights into osteosarcoma targeted therapyCurrent Opinion in Oncology, 2013
- Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibitionMolecular Cancer Therapeutics, 2008
- VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.2008
- The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cellsBlood, 2007
- Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma IntergroupJNCI: Journal of the National Cancer Institute, 2007
- Expression of CD44 variants in osteosarcomaJournal of Cancer Research and Clinical Oncology, 1999